ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pfizer has struck a deal to develop ARV-471, a targeted protein degrader for metastatic breast cancer discovered by Arvinas. Pfizer will pay Arvinas $650 million up front and invest $350 million in the biotech firm. Protein degraders harness the body’s protein disposal system to degrade disease-causing proteins. ARV-471 targets the estrogen receptor, which can cause certain breast cancer cells to grow unchecked. Arvinas was founded in 2013 by Yale University chemical biologist Craig Crews. Pfizer first invested in the firm in 2018.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter